Vioxx, the implosion of Merck, and aftershocks at the FDA
- PMID: 15582041
- DOI: 10.1016/S0140-6736(04)17523-5
Vioxx, the implosion of Merck, and aftershocks at the FDA
Comment in
-
Discontinuation of Vioxx.Lancet. 2005 Jan 1-7;365(9453):23; author reply 26-7. doi: 10.1016/S0140-6736(04)17652-6. Lancet. 2005. PMID: 15639669 No abstract available.
-
Discontinuation of Vioxx.Lancet. 2005 Jan 1-7;365(9453):24. doi: 10.1016/S0140-6736(04)17654-X. Lancet. 2005. PMID: 15639671 No abstract available.
-
Discontinuation of Vioxx.Lancet. 2005 Jan 1-7;365(9453):25-6; author reply 26-7. doi: 10.1016/S0140-6736(04)17657-5. Lancet. 2005. PMID: 15639672 No abstract available.
-
Discontinuation of Vioxx.Lancet. 2005 Jan 1-7;365(9453):25; author reply 27-8. doi: 10.1016/S0140-6736(04)17656-3. Lancet. 2005. PMID: 15639673 No abstract available.
Comment on
-
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.Lancet. 2004 Dec 4-10;364(9450):2021-9. doi: 10.1016/S0140-6736(04)17514-4. Lancet. 2004. PMID: 15582059
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
